Nanostics Inc.: federal grants and contributions: 10 agreements; $1.9M value; 3 departments; 6 programs.
Assay record ASY-CA-0U8U1KG08Y · Cite as: Assay Systems, “Nanostics Inc.: federal grants and contributions”, https://assay-systems.com/register/ca/grants/r/nanostics-inc/
The Nanostics project involves validation of novel biomarkers for ClarityDx Prostate, a prostate cancer diagnostic test that significantly improves the standard of care for prostate cancer from a standard blood draw.
Bladder cancer is the 6th most common cancer in men and the 17th most common cancer in women globally. Early diagnosis of bladder cancer is very important as it is associated with a higher survival rate, for both men and women. There is currently no clinically relevant detection test for bladder cancer. The goal of the Firm's bladder cancer project is to develop a highly accurate test that can detect clinically significant bladder cancer using machine learning and our extracellular vesicle (EV) detection platform. Similar to our successful prostate project we will first validate our selected b
The Nanostics-IRAP project involves refinement and validation of the ClarityDx biomarker panel. ClarityDx is a novel liquid biopsy test that accurately predicts prostate cancer from just a few drops of blood.
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
The funding provided from the IAP program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
The goal of this project is to grow the awareness and adoption of the Firm's prostate test in North America. This novel test that can detect clinically significant prostate cancer via an accurate and minimally invasive test that can reduce healthcare costs and decrease unneeded biopsies and treatments for prostate cancer. The test is currently available in Canada as a laboratory-developed test with appropriate accreditation in the United States. The project will support a targeted key opinion leader campaign that will facilitate regulatory and reimbursement activities that are essential for ma
The purpose of the Canadian International Innovation Program (CIIP) contribution agreement is to support Canadian SMEs identify international partners in CIIP target countries for industrial research and development collaboration that has good potential for commercialization.
Through the application of national and local priorities, the CSJ program seeks to provide youth, particularly those who face barriers to employment with access to work opportunities. Funded employers must demonstrate that they are providing quality work experiences for youth that provide opportunities to develop and improve their skills.
Contains information licensed under the Open Government Licence – Canada. Source: Government of Canada proactive disclosure of grants and contributions (open.canada.ca, dataset 432527ab-7aac-45b5-81d6-7597107a7013), 1,327,352 rows as published, collapsed to one agreement per agreement number (per reference number where none is given) at its latest amendment, which carries the full agreement value. Years are the agreement start year. Agreements with individuals are counted but not named.